Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Chris Lange | Oct 21, 2018 at 10:15 AM EDT

Top Biotech Earnings Reports to Watch This Week

Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Sep 24, 2018 at 10:45 AM EDT

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies…

Lee Jackson | Sep 24, 2018 at 10:25 AM EDT

Jefferies Biotech Growth Picks Have Big Upside Potential

Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut.…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Sep 12, 2018 at 9:55 AM EDT

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with…

Jon C. Ogg | Aug 28, 2018 at 1:45 PM EDT

Are Some Cancer Treatments Becoming Too Expensive to Approve?

The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone…

Chris Lange | Aug 27, 2018 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Lee Jackson | Jul 26, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

The top analyst upgrades, downgrades and other research calls from Thursday include Dolby Laboratories, Facebook, Freeport-McMoRan, Gilead, GrubHub and Skechers.

Chris Lange | Jul 25, 2018 at 4:19 PM EDT

Gilead Earnings Beat Not Enough For Investors

Gilead reported its most recent quarterly results after the markets closed on Wednesday. The major biotech posted $1.91 in earnings…

Chris Lange | Jul 25, 2018 at 12:40 PM EDT

What to Expect When Gilead Reports

Gilead is scheduled to release its second-quarter financial results after the markets close on Wednesday, and analyst expectations are low.

Chris Lange | Jul 25, 2018 at 7:10 AM EDT

Major Biotechs See a Rising Tide of Short Interest

The July 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jul 22, 2018 at 10:25 AM EDT

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger…

1 … 14 15 16 17 18 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Short Sellers Up the Ante in Major Biotechs

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Are Some Cancer Treatments Becoming Too Expensive to Approve?

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

Gilead Earnings Beat Not Enough For Investors

What to Expect When Gilead Reports

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Short Sellers Up the Ante in Major Biotechs

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Are Some Cancer Treatments Becoming Too Expensive to Approve?

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

Gilead Earnings Beat Not Enough For Investors

What to Expect When Gilead Reports

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do